Movement Disorders最新文献

{"title":"Molecular‐Informed Network Analysis Unveils Fatigue‐Related Functional Connectivity in Parkinson's Disease","authors":"Ilaria Antonella Di Vico, Manuela Moretto, Agnese Tamanti, Giovanni Tomelleri, Giulia Burati, Daniel Martins, Ottavia Dipasquale, Mattia Veronese, Alessandra Bertoldo, Elisa Menini, Angela Sandri, Sarah Ottaviani, Francesca Benedetta Pizzini, Michele Tinazzi, Marco Castellaro","doi":"10.1002/mds.30214","DOIUrl":"https://doi.org/10.1002/mds.30214","url":null,"abstract":"BackgroundFatigue in Parkinson's disease (PD) is a prevalent and debilitating non‐motor symptom. Despite its significant impact on quality of life, the underlying neurochemical and network‐based mechanisms remain poorly understood.ObjectivesThis observational study applied a multimodal imaging approach to explore potential links between the functional connectivity of neurotransmitter‐specific circuits and fatigue in a sample of patients with PD.MethodsWe acquired resting‐state functional magnetic resonance imaging data in 35 patients with PD including 18 with clinically significant fatigue and 17 without. We applied the receptor‐enriched analysis of functional connectivity by targets (REACT) pipeline to derive patients' specific molecularly enriched networks informed by the spatial distribution of the dopamine, noradrenaline, serotonin transporters, and metabotropic glutamate 5 receptors as assessed using molecular imaging data in independent samples of healthy controls. We then conducted whole‐brain analyses inspecting both categorical differences between groups of patients with and without clinically significant fatigue, and associations exploring the full within‐sample variation in symptom ratings.ResultsWe found a significant decrease in noradrenaline‐enriched and glutamate‐enriched functional connectivity in key regions, belonging to the sensorimotor, salience, and default mode network, with increasing fatigue severity. Notably, noradrenaline‐enriched functional connectivity reductions were widespread, while glutamate‐enriched functional connectivity reductions were more restricted to the supplementary motor area. No significant relationships between fatigue and dopamine or serotonin‐enriched functional connectivity were found.ConclusionsThese findings offer supportive evidence for the putative involvement of the noradrenaline and glutamate systems in the genesis of fatigue in PD, opening new directions for treatment development exploring these neurochemical systems. © 2025 The Author(s). <jats:italic>Movement Disorders</jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"17 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Memoriam Nir Giladi, MD (1955–2024)","authors":"Serge Przedborski, Bastiaan R. Bloem, Vladimir S. Kostic","doi":"10.1002/mds.30213","DOIUrl":"https://doi.org/10.1002/mds.30213","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"25 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Genetic and Phenotypic Spectrum of Primary Brain Calcification in a Large Cohort from China.","authors":"Zhiru Lin,Dehao Yang,Lebo Wang,Jiaxiang Li,Xinhui Chen,Nan Jin,Yixin Kang,Xinchen Wang,Feng Fu,Haotian Wang,Xiaosheng Zheng,Fei Xie,Zhidong Cen,Wei Luo","doi":"10.1002/mds.30207","DOIUrl":"https://doi.org/10.1002/mds.30207","url":null,"abstract":"BACKGROUNDPrimary brain calcification (PBC) is a monogenic inherited disease characterized by calcifications in basal ganglia and other brain regions, with seven causative genes identified and highly heterogeneous genetic and phenotypic spectrum.OBJECTIVEThe objective was to update the genetic and phenotypic spectrum of PBC in a large cohort from China.METHODSFive hundred eighty-four PBC families were enrolled. Brain calcification was assessed by total calcification score (TCS). Sanger sequencing of SLC20A2 and whole-exome sequencing were performed. Variants were classified by the American College of Medical Genetics and Genomics guidelines.RESULTSEighty-eight probands were genetically diagnosed with pathogenic or likely pathogenic variants in SLC20A2 (75.86%), PDGFRB (2.30%), PDGFB (3.45%), XPR1 (3.45%), MYORG (11.49%), JAM2 (3.45%), and NAA60 (1.15%). Totally, 29 unreported variants were detected. Autosomal recessive PBC (AR-PBC) patients exhibited a higher rate of clinical symptoms compared to those with autosomal dominant PBC (AD-PBC) (100.00% vs. 55.06%, P < 0.001). In all PBC, advancing age showed associations with headache/dizziness (odds ratio [OR] = 0.97, P = 0.0241), cognitive dysfunction (OR = 1.07, P = 0.0025), and psychiatric symptoms (OR = 1.05, P = 0.0396). Regional calcification analysis showed that thalamic calcification scores were associated with cognitive impairment (OR = 1.34, P = 0.0026), followed by lenticular nucleus calcification with headache/dizziness (OR = 1.55, P = 0.0046), cerebellar hemisphere calcification with motor symptoms (OR = 1.45, P = 0.0051), and caudate nucleus calcification with psychiatric manifestations (OR = 1.2, P = 0.0351).CONCLUSIONThis large-scale Chinese cohort study demonstrates the genetic spectrum of PBC and phenotypic characteristics in genetically diagnosed PBC, and also provides genotype-imaging-symptom correlations of PBC. © 2025 International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"28 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform","authors":"Cristina Gonzalez-Robles MD,&nbsp;Dilan Athauda PhD,&nbsp;Thomas R. Barber DPhil, MRCP,&nbsp;Roger A. Barker MRCP, PhD,&nbsp;David T. Dexter PhD, FBPhS,&nbsp;Susan Duty PhD, FBPhS,&nbsp;Romy Ellis-Doyle BSc,&nbsp;Sonia Gandhi PhD,&nbsp;Joel Handley MSc, MRCP,&nbsp;Edwin Jabbari PhD, MRCP,&nbsp;Keith Martin PhD, MRPharmS,&nbsp;Kevin McFarthing PhD,&nbsp;Georgia Mills MRes,&nbsp;Heather Mortiboys PhD,&nbsp;Stephen Mullin PhD,&nbsp;Rebecca Petty MClinRes,&nbsp;Esther Sammler PhD,&nbsp;Paula Scurfield MA,&nbsp;Simon R.W. Stott PhD,&nbsp;George K. Tofaris FRCP, PhD,&nbsp;Li Wei PhD,&nbsp;Caroline H. Williams-Gray FRCP, PhD,&nbsp;Alan Wong MSc,&nbsp;Marie-Louise Zeissler PhD,&nbsp;Richard K. Wyse PhD,&nbsp;Camille B. Carroll MRCP, PhD,&nbsp;Thomas Foltynie FRCP, PhD,&nbsp;Oliver Bandmann MD, PhD,&nbsp;Anthony H.V. Schapira MD, DSc, FRCP, FMedSci,&nbsp;the EJS ACT-PD Consortium","doi":"10.1002/mds.30190","DOIUrl":"10.1002/mds.30190","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions. Compounds were classified into five mechanistic subgroups (mitochondrial, lysosomal, protein, inflammation, “other”). “Go/No-Go” criteria and a scoring system covering preclinical, pharmacological, and clinical evidence were devised. Experts scored the candidates for quantitative rankings. Dossiers adapted from iLCT documents were produced for the top-ranked compounds and in turn prioritized by the TSWG. Practical and logistical considerations from the Steering Committee (SC) guided the final decision. Patient and Public Involvement and Engagement representatives provided feedback throughout the process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 293 interventions were identified, 52 of which passed the “Go/No-Go” criteria and were scored. Dossiers of the 14 top-ranked compounds were submitted to the SC. Telmisartan, terazosin, and ursodeoxycholic acid were selected as the initial interventions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Drug selection in DMT PD MAMS trials requires consideration of scientific and practical issues. We present a robust system that can inform similar initiatives. © 2025 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 7","pages":"1307-1317"},"PeriodicalIF":7.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.30190","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"April Infographic","authors":"","doi":"10.1002/mds.29847","DOIUrl":"https://doi.org/10.1002/mds.29847","url":null,"abstract":"<p>\u0000 \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 TDP-43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP-43 Proteinopathies</p>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 4","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/10.1002/mds.29847","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the International Parkinson and Movement Disorder Society Non-Motor Symptoms Questionnaire (MDS-NMS-Q)","authors":"Daniel Weintraub MD,&nbsp;Kallol Ray Chaudhuri MD, DSc,&nbsp;Anette Schrag FRCP, PhD,&nbsp;Pablo Martinez-Martin MD, PhD,&nbsp;Alexandra Rizos MSc,&nbsp;Eugenia Mamikonyan MS,&nbsp;Julia Gallagher BS,&nbsp;Izabelle Schoen BA,&nbsp;Juliet Staunton MSc,&nbsp;Marta Pereira Fernandes BSc, RN,&nbsp;Carmen Rodriguez-Blazquez PhD","doi":"10.1002/mds.30202","DOIUrl":"10.1002/mds.30202","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) assesses severity and frequency of non-motor symptoms (NMS) in Parkinson's disease (PD) and is rater-administered. The MDS-NMS Questionnaire (MDS-NMS-Q), developed as a briefer (i.e., assessing symptom severity only), self-completed version of the MDS-NMS, is also a 13-domain, 52-symptom instrument with a separate non-motor fluctuations (NMFs) section.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The goal was to validate the MDS-NMS-Q versus the MDS-NMS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional, multi-site, international study was conducted with idiopathic PD patients. After completing the self-administered MDS-NMS-Q unsupervised, patients were assessed with the rater-administered MDS-NMS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cohort consisted of 199 PD patients (mean age [±standard deviation (SD)] = 67.19 [±9.95] years; mean age at PD diagnosis [±SD] = 59.27 [±9.54] years); median Hoehn and Yahr stage = 2. Data quality was satisfactory for all 13 MDS-NMS-Q domains. There were no floor or ceiling effects for the total score; individual domains had no appreciable ceiling effects, but variable floor effects (5.0%–71.4%). Internal consistency for most domains was satisfactory, except for the impulse control domain (Cronbach's α ≥0.75 for 10/13 domains). Correlation and concordance between MDS-NMS-Q and MDS-NMS total scores were high (Spearman rank correlation coefficient = 0.86; Kendall's coefficient of concordance = 0.93).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The MDS-NMS-Q has a strong association and concordance with the MDS-NMS at the total score and domain level. This indicates that the MDS-NMS-Q, allowing self-completion and focusing only on symptom severity, is an acceptable alternative to rater administration assessing both severity and frequency. © 2025 International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 6","pages":"1037-1046"},"PeriodicalIF":7.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.30202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease","authors":"Alex I. Wiesman, Mikkel C. Vinding, Panagiota Tsitsi, Per Svenningsson, Josefine Waldthaler, Daniel Lundqvist","doi":"10.1002/mds.30200","DOIUrl":"https://doi.org/10.1002/mds.30200","url":null,"abstract":"BackgroundIndividual variability in clinical response to dopamine replacement therapy (DRT) is a key barrier to efficacious treatment for patients with Parkinson's disease (PD). A better understanding of the neurobiological sources of such interindividual differences is necessary to personalize DRT prescribing, inform future clinical interventions, and motivate translational research.ObjectiveOne potential source of this variability is an unintended secondary activation of extra‐nigrostriatal dopamine systems by DRT, particularly in the neocortex. Our goal was to determine the clinical effects of cortical dopamine system activation by DRT in patients with PD.MethodsWe used pharmaco‐magnetoencephalography data collected from patients with PD (N<jats:sub>PD</jats:sub> = 17, N<jats:sub>HC</jats:sub> = 20) before and after DRT to map their cortical neurophysiological responses to dopaminergic pharmacotherapy. By combining these DRT response maps with normative atlases of cortical dopamine system densities, we linked the variable enhancement of rhythmic cortical activity by DRT to dopamine‐rich cortical regions and determined its clinical relevance.ResultsWe found beta‐rhythmic responses to DRT in dopamine‐rich regions of the cortex that are expressed variably across individuals. Importantly, patients who exhibited a larger dopaminergic beta cortical enhancement showed a smaller clinical improvement from DRT, indicating a potential source of individual variability in medication response for patients with PD.ConclusionsWe conclude that these findings inform our understanding of the dopaminergic basis of neurophysiological variability often seen in patients with PD, and indicate that our methodological approach may be useful for data‐driven contextualization of medication effects on cortical neurophysiology in future research and clinical applications. © 2025 The Author(s). <jats:italic>Movement Disorders</jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"32 1","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Movement Disorders: Volume 40, Number 4, April 2025","authors":"","doi":"10.1002/mds.30204","DOIUrl":"https://doi.org/10.1002/mds.30204","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 4","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.30204","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143845954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE)","authors":"Matthew D. Smith BMBS, PhD,&nbsp;Gabriella E. Portlock BSc,&nbsp;Anisha Cullen MEng,&nbsp;Anahita Nodehi PhD,&nbsp;Marcus J. Drake BMBCh, DM,&nbsp;Yoav Ben-Shlomo MBBS, PhD,&nbsp;Emily J. Henderson MBChB, PhD","doi":"10.1002/mds.30186","DOIUrl":"10.1002/mds.30186","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lower urinary tract symptoms (LUTS) are common Parkinson's disease (PD), causing great impact.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The goal was to undertake a phase II randomized control trial of transcutaneous tibial nerve stimulation (TTNS) delivered by Geko device for LUTS related to overactive bladder (OAB) in PD, an easy to use of the shelf solution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants were randomized to active/sham stimulation. Primary outcome measure was the International Consultation on Incontinence Questionnaire-Overactive Bladder score (ICIQ-OAB) at 12 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 148 participants were allocated to active (73) and sham arms (75). No difference was seen between arms (coefficient, 0.48; 95% CI, −0.2 to 1.2; <i>P</i> = 0.17), although both active and sham showed improvements over baseline. Pain was the most common adverse event.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>No difference was seen between active and sham arms. Symptom improvements seen in both groups are consistent with a placebo effect, however, we cannot exclude a biological effect from the sham intervention. Although negative, this result should be taken only in context of Geko use rather TTNS in general. © 2025 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 7","pages":"1291-1296"},"PeriodicalIF":7.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.30186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in Essential Tremor: A Systematic Review and Metanalysis","authors":"Alyssa Shiramba MRes,&nbsp;Steven Lane PhD,&nbsp;Nicola Ray PhD,&nbsp;Tom Gilbertson MD, MRCP, PhD,&nbsp;Rajesha Srinivasaiah MD, MRCP,&nbsp;Jay Panicker MD, MRCP,&nbsp;Mark Radon MD, MRCP,&nbsp;Jibril Osman-Farah MD, FRCS,&nbsp;Antonella Macerollo MD, FRCP, PhD","doi":"10.1002/mds.30188","DOIUrl":"10.1002/mds.30188","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Magnetic resonance-guided focused ultrasound (MRgFUS) is an established surgical treatment for essential tremor, providing tremor relief without the need for an incision or general anesthesia. Meta-analyses have been limited in their exploration of the durability of the treatment effect.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The study aimed to assess the treatment effect and safety of this procedure over time. Different to other meta-analyses, this study assessed the durability of efficacy over time from 1 month to 5 years follow-up. Investigating the recurrence of tremor was an important target of this work.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search of the literature utilizing set search criteria was conducted with the PubMed, Scopus, Web of Science, and Cochrane library databases, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data analysis was conducted in R, utilizing a random-effects model for meta-analysis and a mixed-effects model for meta-regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-five studies met the inclusion criteria, of which 42 were included in the analyses. Significant changes in hand tremor, total tremor, disability scores, and quality of life scores were demonstrated across the time points investigated, the pooled standardized mean differences being −2.36 (<i>P</i> &lt; 0.0001), −2.08 (<i>P</i> &lt; 0.0001), −2.85 (<i>P</i> &lt; 0.0001), and −1.41 (<i>P</i> &lt; 0.0001) 1 year post-operation. Sensory symptoms and unsteadiness adverse events were frequently observed, with pooled proportions of 22% (95% CI 15%; 31%) and 23% (95% CI 16%; 31%) 1 month post-MRgFUS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although the procedure demonstrated efficacy and safety across the studies evaluated, meta-regression analysis suggests a decrease in treatment effect over time that requires further investigation. © 2025 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 6","pages":"1020-1033"},"PeriodicalIF":7.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.30188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}